IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study
Yang, Li1; Christensen, Torsten2; Sun, Fengyu3; Chang, Jinghua3
关键词Chinese setting cost-effectiveness cost-utility insulin detemir
刊名VALUE IN HEALTH
2012
DOI10.1016/j.jval.2011.11.018
suppl.S期:1页:S56-S59
收录类别SCI ; SSCI
文章类型Article
WOS标题词Social Sciences ; Science & Technology
类目[WOS]Economics ; Health Care Sciences & Services ; Health Policy & Services
研究领域[WOS]Business & Economics ; Health Care Sciences & Services
关键词[WOS]THERAPY CONVERSION ; MELLITUS ; OUTCOMES ; ASPART
英文摘要

Objectives: To evaluate the long-term cost-effectiveness of switching from insulin glargine (IGla) to insulin detemir (IDet) in patients with type 2 diabetes in the setting of Chinese secondary and tertiary hospitals. Methods: A published and validated computer simulation model of diabetes (the Center for Outcomes Research model) was used to make the long-term (30 years) projection of health economic outcomes. Patient demographic information and clinical end points were derived from a subgroup analysis of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation (PREDICTIVE) study. Baseline risk factors and racial characteristic data were obtained from Chinese cohort studies. The diabetes management and complications costs were obtained from Chinese published data and adjusted to 2010 values by using the Chinese consumer price index. An annual discounting rate of 3% was used for both health and cost outcomes, and one-way sensitivities analysis was performed, which illustrated that the results were robust. Results: Conversion to IDet from IGla was projected to improve patient life expectancy by 0.06 year and 0.48 quality-adjusted life-years. Drug costs and management costs of diabetes mellitus were increased by US$368 (US$17,466 vs. US$17,097) and US$31 (US$5464 vs. US$5433), respectively. However, the costs of complications, including cerebrovascular disease, renal complications, ulcer/amputation/neuropathy, eye complications, and hypoglycemia events, were reduced by US$ 819 (US$21,294 vs. US$22,114), resulting in a total direct medical cost saving of US$420 when converting to IDet. Conclusions: Conversion to IDet from an IGla regimen improved life expectancy and was a cost-saving treatment approach in a Chinese setting.

语种英语
WOS记录号WOS:000299317000010
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61629
专题北京大学公共卫生学院
作者单位1.Novo Nordisk AS, Virum, Denmark
2.Novo Nordisk China Pharmaceut Co Ltd, Beijing, Peoples R China
3.Peking Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Yang, Li,Christensen, Torsten,Sun, Fengyu,et al. Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study[J]. VALUE IN HEALTH,2012,suppl.S(1):S56-S59.
APA Yang, Li,Christensen, Torsten,Sun, Fengyu,&Chang, Jinghua.(2012).Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study.VALUE IN HEALTH,suppl.S(1),S56-S59.
MLA Yang, Li,et al."Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study".VALUE IN HEALTH suppl.S.1(2012):S56-S59.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Li]的文章
[Christensen, Torsten]的文章
[Sun, Fengyu]的文章
百度学术
百度学术中相似的文章
[Yang, Li]的文章
[Christensen, Torsten]的文章
[Sun, Fengyu]的文章
必应学术
必应学术中相似的文章
[Yang, Li]的文章
[Christensen, Torsten]的文章
[Sun, Fengyu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。